

DEVICE AND IMAGE ANALYSIS ADVANCEMENTS TOWARDS PHOTOACOUSTIC AND ULTRASOUND TOMOGRAPHY-GUIDED PROSTATE BIOPSY

Brittani L. Bungart

February 11, 2019



Slides can be found online at <http://phd-defense.brittanibungart.com>.

Outline

INTRODUCTION

- Prostate cancer significance and background
- Identification of clinical need and engineering gaps

EX VIVO PROSTATE IMAGING STUDY FOR IDENTIFYING BIOPSY TARGETS

- Development of *ex vivo* PAT/US imaging system
- Image analysis to identify prostate biopsy targets using endogenous contrast PAT and US imaging


IN VIVO PAT/US IMAGING DEVICE DEVELOPMENT

- Background on illumination delivery
- Development of effective transurethral light delivery device

CONCLUSIONS AND FUTURE DIRECTIONS

Significance: Prostate Cancer

- Most common visceral cancer in men
- ~1 in 6 men develop prostate cancer in their lifetime
- 5 year survival rate = 98.2%
Drops to 29% if metastasized prior to diagnosis
- ~1 in 32 men die from prostate cancer




Overdiagnosis and overtreatment of prostate cancer is of major concern within the medical community.



What Is the Most Important Component for Diagnosis?

Diagnostic confirmation:

Tissue biopsy¹ with pathologic analysis.



Schematic of cores (arrows) taken during biopsy using prior clinical standard².



Example Gleason Grades³. (A) $3+3 = 6$; (B) $3+4 = 7a$; (C) $4+3 = 7b$; (D-F) $4+4 = 8$.

Problem Background


Two Major Reasons for Overdiagnosis/Overtreatment

- Prostate Specific Antigen (PSA)
- 12-76% do not have prostate cancer
- Elevation not specific to prostate cancer (transient and chronic causes)
 - Benign Prostatic Hyperplasia
 - Prostatitis
 - Others
- Transrectal Ultrasound-guided Core Biopsy
 - 12 random cores taken systematically
 - 12% repeat biopsy following negative result within 1 year
 - 38% within 5 years


High false positive rate

High false negative rate

Problem Background



Schematic of cores (arrows) taken during biopsy using prior clinical standard².




Untargeted sampling
of <1 – 3% of prostate

- Transrectal Ultrasound-guided Core Biopsy
- 12 random cores taken systematically
- 12% repeat biopsy following negative result within 1 year
 - 38% within 5 years


High false negative rate

Recent Clinical Update: MRI Fusion Biopsy


Magnetic Resonance Imaging (MRI) machine




T2-weighted image





Dynamic C-E Image*





Diffusion Coef. Image



MRI read by Radiologist.
Outline targets



Ultrasound with "fused"
MRI outlines.




MRI T2-weighted
image. Target
outlined in green.
Red outline marks
the prostate
boundary.

Disadvantages of MRI-Fusion Biopsy

Transrectal Ultrasound


- Real-time imaging
- Patient awake



Ultrasound with “fused” MRI outlines.

MRI


- Static image
- Separate appointment
- Patient in different position



MRI T2-weighted image.

GAP: Real-time targeted prostate cancer biopsy

Photoacoustic Tomography Basic Principle







Factors that Influence Signal

- Local light fluence (F)
- Absorber concentration ($[A]$)
- Absorber coefficient of absorption (μ_a)
- Environment characteristics related to expansion, acoustic speed, and specific heat (Gruneisen parameter; Γ)

$$\text{PA signal} = \mu_a \Gamma F [A]$$


Signal collected by US transducers, which are used for current prostate biopsy.

Photoacoustic Tomography of Prostate




Remaining Engineering Design Needs

Aim 1: Identify tumors without manual selection in images acquired in a more clinically-relevant manner.




Aim 2: Improve light delivery to enable anterior prostate PAT imaging.




Biomarker for Photoacoustic Tomography


Cholesteryl Ester - a potential marker of prostate cancer aggressiveness



Vibrational Photoacoustic Tomography – Ji-Xin Cheng Lab pioneered lipid as contrast



Photoacoustic Tomography System at IU Hospital




Ultrasound frequency range: 4.6 – 9 MHz

Wavelength outputs: 1064 & 1197 nm


M1: 45 degree reflective mirror; M2: flip-mounted 45 degree reflective mirror; M3: resonator end mirror; M4: output coupler; PBS: polarizing beam splitter; HWP: half wave plate; QWP: quarter wave plate; BdN: barium dinitrite crystal; BFB: bifurcated fiber bundle; UST: ultrasound transducer; DAQ: data acquisition system.



PAT/US Probe for Ex Vivo Prostate Imaging




Bifurcated PAT/US Probe V1 for Ex Vivo Prostate Imaging



Pros: Compact design

Cons: Focus too close to US


Colinear PAT/US Probe for Ex Vivo Prostate Imaging



Pros: Aligned light and acoustic path

Cons: Bulky design; Complex; Lower SNR

Bifurcated PAT/US Probe V2 for Ex Vivo Prostate Imaging





Pros: Simple design; Deeper PAT imaging

Cons: Too bulky for *in vivo*



Use this design for *ex vivo* human prostate imaging.

Human Prostate Handling and Imaging




Acquire: 1197 AND 1064 nm PA and US data


Imaging plane: AXIAL (to match pathology)



Intensity Thresholding-based Analysis Ineffective



Texture-based K-means Clustering Feature Learning





Texture Analysis Underlying Theory

Prostate cancer is strongly associated with neovascularization.

- NOT specific to prostate cancer though...BPH also exhibits

Morphology KEY with unique changes in gland structure.

Analysis based on premise of different vasculature topology and not density (intensity).




Example Gleason Scores.

Dataset Characteristics


Training Dataset (prostates=6)	
Age	61 +/- 9
Prostate Volume (cm ²)	82.3 +/- 26.0
Primary Lesion Largest Dimension (cm)	2.79 +/- 1.1
Secondary Lesion Largest Dimension (cm)	1.0 +/- 0.4
Gleason 6	1
Gleason 7a	3
Gleason 7b	2
Gleason 8-10	0
Testing Dataset (prostates=3)	
Age	72 +/- 7
Prostate Volume (cm ²)	96.4 +/- 23.3
Primary Lesion Largest Dimension (cm)	1.9 +/- 1.0
Secondary Lesion Largest Dimension (cm)	1.2 +/- 0.6
Gleason 6	0
Gleason 7a	2
Gleason 7b	1
Gleason 8-10	0

1197 nm PAT Does Not Provide Unique Information




1197 nm PAT Does Not Provide Unique Information


Cholesteryl Ester - a potential marker of prostate cancer aggressiveness




$$\text{PA signal} = \mu_a \Gamma F[A]$$




Prostate Biopsy Targets Identified in Testing Dataset



Need Improved Light Fluence to Anterior Prostate



Need Improved Light Fluence to Anterior Prostate




Light Delivery Approaches for Prostate


1. Transrectal

2. Transperineal

3. Transurethral




Simulation Study on Light Delivery




Use transurethral illumination with transrectal US.

Prior Advancements for Transurethral Light Delivery



(a)

(b)




(b)

(c)




(d)

1 cm

Transurethral Light Delivery Device V1




Fiber Bundle Layout with Side-firing Fibers




Use 44° for bevel tip.

Transurethral Bevel-tipped Fiber Bundle


A




B





C



D






Bevel-tipped Fiber Bundle Performance




Transurethral Light Delivery Device V2


A





D





Need cylindrical
illumination.



Prior literature on High Energy Cylindrical Emitters




Fiber with Sandpaper-abraded Diffuser End



PAT/US System with Transurethral Illumination







Changes to PAT/US System:

1. Uncoupled illumination source and detector
2. 6W Nd:YAG laser with 8 ns pulse width
3. Galilean beam reducer




DE: diffuser end; ACL: angularly-coupled light; MMF: multimode fiber; UST: ultrasound transducer; DAQ Trig: data acquisition system trigger; M: Nd:YAG laser line 45° mirror; HWP: half wave plate; PBS: polarized beam splitter; GBR: Galilean beam reducer; 3-DS on RS: 3-dimensional stage on rotational stage; DE+P: diffuser end + phantom.


Coupling Angle Affects Side Emission Conversion




Coupling Angle Affects Longitudinal Emission Profile



Energy Profiles Stable and Allow Calculation of Fluence



Angular Coupling Enables PA Signal from Whole Phantom




Conclusions

1. Bifurcated PAT/US imaging device with angled fiber bundles is the best design for *ex vivo* prostate imaging.
2. Texture-based image processing with K-means feature learning has the potential to identify biopsy targets using 1064 nm PAT and US imaging.
3. Sandpaper micro-machining method to fabricate fibers with diffuser ends is simple, safe, and resource efficient.
4. Angular coupling of light into cylindrical diffusing fiber improves forward propagating to side firing conversion to enable transurethral light deliver.

Future Directions

1. Improve transurethral fiber design by making more flexible and couple more energy
 - <OD core fiber; >pulse width
2. *Incorporate dual light illumination
3. *In vivo* imaging study
4. Exogenous contrast



Acknowledgments

CO-MENTORS

Ji-Xin Cheng, PhD
Young Kim, PhD

THESIS COMMITTEE

Craig Goergen, PhD
Timothy Masterson, MD

CHENG LAB MEMBERS

Pu Wang, PhD
Rui Li, PhD
Lu Lan
Yingchun Cao, PhD
Jie Hui, PhD
Jiayingzi Wu
Delong Zhang, PhD
Hyeon Jeon Lee, PhD
Yi Zhang
Tiffany Yang-Tran

COLLABORATORS

Michael Koch, MD
Liang Cheng, MD
Timothy Ratliff, PhD
Murat Dundar, PhD
Darren Roblyer, PhD
Sean Gorsky
Emil Atz

FUNDING SOURCES

Walther Cancer Foundation
Indiana Clinical and Translational Science
Institute
Bilsland Dissertation Fellowship

ADDITIONAL SUPPORT

IU MSTP
Raghu Mirmira, MD PhD
Maureen Harrington, PhD
Janice Receveur
Lauren Lynch
Weldon School of BME
Andrew Brightman, PhD
Sherry Harbin, PhD
Linda Doyle
Sandra May
Susan Hardy
Bill Schoenlein
BU Photonics Center and ECE Dept.

